Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H4N4O3 |
| Molecular Weight | 168.1103 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=C(N1)C(=O)NC(=O)N2
InChI
InChIKey=LEHOTFFKMJEONL-UHFFFAOYSA-N
InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)
| Molecular Formula | C5H4N4O3 |
| Molecular Weight | 168.1103 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25422986Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/dict/uric-acid.html | http://www.wikidoc.org/index.php/Uric_acid
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25422986
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/dict/uric-acid.html | http://www.wikidoc.org/index.php/Uric_acid
Uric acid, generated from the metabolism of purines, has proven and emerging roles in human disease. Humans produce large quantities of uric acid. Excess serum accumulation of uric acid can lead to a type of arthritis known as gout. Hyperuricemia may increase risk factors for cardiovascular disease. High serum uric acid was associated with higher risk of type 2 diabetes and other diseases.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Urate oxidase (mammals) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2594778 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Superoxide mediates shock wave induction of ERK-dependent osteogenic transcription factor (CBFA1) and mesenchymal cell differentiation toward osteoprogenitors. | 2002-03-29 |
|
| Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. | 2002-01 |
|
| Electrosynthesis of poly-o-diaminobenzene on the Prussian Blue modified electrodes for improvement of hydrogen peroxide transducer characteristics. | 2002-01 |
|
| Allantoin formation and urate and glutathione exchange in human muscle during submaximal exercise. | 2001-12-01 |
|
| Water-soluble antioxidants in human tears: effect of the collection method. | 2001-12 |
|
| Oxidative stress in lavage fluid of preterm infants at risk of chronic lung disease. | 2001-12 |
|
| Localization and topology of a urate transporter/channel, a galectin, in epithelium-derived cells. | 2001-12 |
|
| Isolation and characterization of the DLAD/Dlad genes, which lie head-to-head with the genes for urate oxidase. | 2001-11-16 |
|
| Respiratory and circulatory compensation to hypoxia in crustaceans. | 2001-11-15 |
|
| Modulators of haemocyanin oxygen affinity in the hypoxia- and sulphide-tolerant Baltic isopod Saduria entomon (L.). | 2001-11 |
|
| Intracellular pH, intrauterine growth and the insulin resistance syndrome. | 2001-11 |
|
| Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. | 2001-11 |
|
| Nephrocalcinosis in preterm babies. | 2001-11 |
|
| Expression of the urate transporter/channel is developmentally regulated in human kidneys. | 2001-11 |
|
| Temperature-sensitive phenotype of Chinese hamster ovary cells defective in PEX5 gene. | 2001-10-26 |
|
| Influence of plasma glutathione levels on radiation mucositis. | 2001-10-01 |
|
| Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. | 2001-10 |
|
| European experience in the treatment of hyperuricemia. | 2001-10 |
|
| Tumor lysis syndrome. | 2001-10 |
|
| Gout: radiographic findings mimicking infection. | 2001-10 |
|
| Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. | 2001-10 |
|
| Ozone causes lipid peroxidation but little antioxidant depletion in exercising and nonexercising hamsters. | 2001-10 |
|
| Suicide inactivation of xanthine oxidoreductase during reduction of inorganic nitrite to nitric oxide. | 2001-09-01 |
|
| Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. | 2001-09 |
|
| Synthesis of ascorbate and urate in the ovary of water buffalo. | 2001-09 |
|
| Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis. | 2001-09 |
|
| A family-based study of metabolic phenotypes in calcium urolithiasis. | 2001-09 |
|
| Recurrent renal stone disease-advances in pathogenesis and clinical management. | 2001-08-25 |
|
| The cyclooxygenase hydroperoxide product PGG(2) activates synaptic nitric oxide synthase: a possible antioxidant response to membrane lipid peroxidation. | 2001-08-17 |
|
| Photosensitizer initiated attacks on DNA under dry conditions and their inhibition: a DNA archiving issue. | 2001-08-15 |
|
| Experimental meningitis in the rat: protection by uric acid at human physiological blood concentrations. | 2001-08-10 |
|
| Hydrogen peroxide damages the zinc-binding site of zinc-deficient Cu,Zn superoxide dismutase. | 2001-08-01 |
|
| Flow-through chemiluminescence sensor using immobilized oxidases for the selective determination of L-glutamate in a flow-injection system. | 2001-08 |
|
| Redox reactions of the urate radical/urate couple with the superoxide radical anion, the tryptophan neutral radical and selected flavonoids in neutral aqueous solutions. | 2001-08 |
|
| Plasma concentrations of alpha-tocopherol and urate in patients with different types of cancer. | 2001-08 |
|
| Laryngeal manifestation of gout: a case report of a subglottic gout tophus. | 2001-08 |
|
| Uric acid or urate nephropathy? | 2001-08 |
|
| Biochemical profile of idiopathic uric acid nephrolithiasis. | 2001-08 |
|
| Self-treatment for gout. | 2001-08 |
|
| Ascorbate dynamics and oxygen consumption during arousal from hibernation in Arctic ground squirrels. | 2001-08 |
|
| Immunological properties of uricase conjugated to neutral soluble polymers. | 2001-07-19 |
|
| Gouty tenosynovitis of the wrist. | 2001-07 |
|
| [Relationship between severity of essential arterial hypertension and the prevalence hyperuricemia]. | 2001-06-23 |
|
| Low-expression genes induced by nitrogen starvation and subsequent sexual differentiation in Chlamydomonas reinhardtii, isolated by the differential display technique. | 2001-06 |
|
| Flavonoids and urate antioxidant interplay in plasma oxidative stress. | 2001-05 |
|
| Serum cystatin C is a better marker for preeclampsia than serum creatinine or serum urate. | 2001 |
|
| Comparison of the efficacy of two anti-uric acid diets in dalmatian dogs. | 2001 |
|
| Is skeletal muscle damaged by the oxidative stress following anaerobic exercise? | 2001 |
|
| Tumoral calcium pyrophosphate dihydrate crystal deposition disease. A clinicopathologic analysis of five cases. | 2001 |
|
| Mouse paracentric inversion In(3)55Rk mutates the urate oxidase gene. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435251
Mice: twice daily with 10 mg per dose for 7 days
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12743010
Uric acid (5 mg/dL) significantly increased MCP-1 production by rat vascular smooth muscle cells at 3, 6, and 24 hours when compared with that of control media.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:20 GMT 2025
by
admin
on
Mon Mar 31 17:50:20 GMT 2025
|
| Record UNII |
268B43MJ25
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1916
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
||
|
DSLD |
3056 (Number of products:1)
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
||
|
CFR |
21 CFR 862.1775
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB08844
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
200-720-7
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
SUB32801
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
100000126333
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
69-93-2
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
DTXSID3042508
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
17775
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
1427088
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
268B43MJ25
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
D014527
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
3975
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
C62652
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
m11330
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
1175
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
268B43MJ25
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
URIC ACID
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
INHIBITOR OF FORMATION->TARGET |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
INHIBITOR OF FORMATION->TARGET |
|
||
|
ENZYME->SUBSTRATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> SUBSTRATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|